Results 1 to 10 of about 77,611 (167)

Bevacizumab [PDF]

The Oncologist, 2010
AbstractLearning ObjectivesAfter completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to ...
Kazazi-Hyseni, F., Beijnen, J.H., Schellens, J.H.M.   +2 more
openaire   +4 more sources

Bevacizumab (Avastin) [PDF]

American Journal of Neuroradiology, 2009
Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
openaire   +2 more sources

Intravitreal bevacizumab

Indian Journal of Ophthalmology, 2018
openaire   +3 more sources

Effectiveness of primary tumor resection for survival after first-line cetuximab or bevacizumab in KRAS wild-type metastatic colorectal cancer treated with subsequent trifluridine/tipiracil or regorafenib. [PDF]

Ann Coloproctol
Chen YH, Wu CC, Su CC, Lee PT, Su YC.
europepmc   +1 more source

Effect of intravitreal bevacizumab on kidney function and proteinuria among diabetic patients: a prospective observational study in Asian population. [PDF]

Ren Fail
Mourya B, Sangha SS, Kumar A, P T, Yadav RK, Bhowmik D, Agarwal SK, Sinha R, Azad SV.   +8 more
europepmc   +1 more source

Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study. [PDF]

BMC Cancer
Sucuoğlu İşleyen Z, Seçmeler Ş, Sakin A, Cihan Ş, Beşiroğlu M, Kahraman S, Karakurt Eryılmaz M, Zeynelgil E, Çalışkan Yıldırım E, Kut E, Şengül N, Paksoy Türköz F, Alan Ö, Özkul Ö, Işık S, Yılmaz F, Gülmez A, Türker S, Karakaya G, Günaldı M, Özer L, Aksoy A, Karataş F, Sakalar T, Demirtaş Esmer D, Teker F, Demir N, Dülgar Ö, Turhal S, Türk HM, Ertürk K, Çelik E, Atcı MM.   +32 more
europepmc   +1 more source

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy. [PDF]

Int J Ophthalmol
Joo JY, Jun YH, Kim ST.
europepmc   +1 more source

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. [PDF]

Ther Adv Med Oncol
Qi H, Huang Y, Zhang W, Li J, Wang T, Ying Y, Chen B, Miao F, Li Q.   +8 more
europepmc   +1 more source

Intralesional bevacizumab as an adjuvant approach to recurrent respiratory papillomatosis: A prospective study on different treatment protocols. [PDF]

PLoS One
Klimza H, Zakrzewski B, Porębski A, Wierzbicka M.   +3 more
europepmc   +1 more source

The Effect of Bevacizumab Therapy on Reducing Erythrocyte Transfusion Requirements and Preventing Iron Deficiency in Patients With Hereditary Hemorrhagic Telangiectasia. [PDF]

Cureus
Aydın Ö, Köseoğlu FD, Sayın S, Gözden HE, Şahin O, Ataş Ü, Kürekci DD, Aktimur SH, Aylı M, Turgut M, Güven S.   +10 more
europepmc   +1 more source